Most people will experience infection with human papilloma virus (HPV) at some point in their life. Diagnosis, based on clinical examination, is usually straight forward. Treatment can, however, be challenging.
Indications for treatment include pain, interference with function, cosmetic embarrassment, and risk of malignancy. Clearance rates are highest in young, healthy individuals with short duration of infection.
Treatment may be with destructive agents (keratolytics, cryotherapy, curettage and cautery, laser, photodynamic therapy), with antimitotic agents (podophyllin, bleomycin, retinoids), with immune stimulants (topical sensitizers, cimetidine), or with topical virucidal agents [formaldehyde (formalin), glutaral (gluteraldehyde)].
As yet, there is no single totally effective treatment for viral warts. Some patients may choose to leave their warts untreated until spontaneous resolution. In those who seek intervention, simple, well tolerated therapies should be chosen initially in preference to more complicated, potentially harmful agents. It is likely that future research will be directed to developing an antiviral agent specific for HPV which would be safe, effective and not prohibitively expensive.
Salicylic Acid Human Papilloma Virus Imiquimod Human Papilloma Virus Infection Cantharidin
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Stazzone A., Borgs P., Witte C., et al. Lymphangitis and refractory lymphoedema after treatment of topical cantharidin. Arch Dermatol 1998; 134: 105–106CrossRefGoogle Scholar
Boyle J., Dick D.C., Maclde R.M. Treatment of extensive viral warts with etretinate in a patient with sarcoid. Clin Exp Dermatol 1983; 8: 33–36PubMedCrossRefGoogle Scholar
Gross G., Pfister H., Hagedorn M., et al. Effect of oral aromatic retinoid (Ro 9359) on human papilloma virus -2 induced common warts. Dermatologica 1983; 166: 48–53PubMedCrossRefGoogle Scholar
Rogozinski T., Geizer J.M., Czametzki B.M., et al. Acitretin in the treatment and prevention of viral, premalignant and malignant skin lesions. J Dermatol Treat1989; 1: 91–93CrossRefGoogle Scholar
Euvarard S., Vershooreu M., Touraine J.L., et al. Topical retinoids for warts and keratoses in renal transplant recipients. Lancet 1992; 340: 48–49CrossRefGoogle Scholar
Shuttleworth D., Marks R., Griffin P.J.A., et al. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1998; 68: 717–724Google Scholar
Pazin G.J., Ho M., Haveros H.W., et al. Effects of interferon alpha in human warts. J Interferon Res 1982; 2: 235–243PubMedCrossRefGoogle Scholar
Gibson J.R., Harvey S.G., Kemmett D.K., et al. Treatment of common and plantar warts with human lymphoblastoid intereferon alpha: pilot studies with intralesional and intramuscular and dermojet injections. Br J Dermatol 1986; 115 Suppl. 31: 76–79PubMedCrossRefGoogle Scholar
Vance J.C., Bart B.J., Hansen R.C., et al. Intralesional recombinant interferon for the treatment of patients with conylomata accuminata or verruca plantaris. Arch Dermatol 1986; 122: 272–277PubMedCrossRefGoogle Scholar
Berman B., Davis Reed L., Silverstein L., et al. Treatment of verrucal vulgaris with alpha 2 interferon. J Infect Dis 1986; 154: 328–330PubMedCrossRefGoogle Scholar
Pazin G.J., Ho M., Haverkos H.W., et al. Effects of interferon alpha in human warts. J Interfer Res 1982; 2: 235–243CrossRefGoogle Scholar
Buckner D., Price N. Immunotherapy of verrucae vulgaris with dinitrochlorobenzene.Br J Dermatol 1978; 98: 451–455PubMedCrossRefGoogle Scholar
Young H.R. DNCB reported effective for recalcitrant warts. Skin Allergy News1976; 7: 19Google Scholar
Orrechia G., Douville H., Santagostina L., et al. Treatment of multiple relapsing warts with diphencyprone. Dermatologica 1988; 177: 225–231CrossRefGoogle Scholar
Naylor M.F., Nelder K.H., Yarborough G.K., et al. Contact immunotherapy of resistant warts. J Am Acad Dermatol 1988; 19 (4): 679–683PubMedCrossRefGoogle Scholar
Lee A.N., Mallory S.B. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. J Am Acad Dermatol 1999; 41: 595–599PubMedGoogle Scholar
Schon M., Helin P. Levamisole in a double blind study. No effect on warts. Acta Derm Venereol 1977; 57: 449–454Google Scholar
Benton E.C., Nolan M.W., Kemmett D.K., et al. Trial of inosine pranobex in the management of cutaneous warts. J Dermatol Treat 1991; 1: 295–297CrossRefGoogle Scholar
Orlow S.J., Paller A. Cimetidine therapy for multiple viral warts in children. J Am Acad Dermatol 1993; 28: 794–796PubMedCrossRefGoogle Scholar
Bourke J.F., Berth-Jones J., Hutchison P.E. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol 1990; 132: 115–120Google Scholar
Street M.L., Roenigk R.K. Recalcitrant periungal verrucae: the role of carbon dioxide laser vaporisation. J Am Acad Dermatol 1990; 132: 115–120CrossRefGoogle Scholar
Jain A., Sorwick G.S. Effectiveness of the 585 run flashlamp tunable dye laser (PDTL) for treatment of plantar verrucae. Lasers Sug Med 1997; 21 (5): 500–505CrossRefGoogle Scholar
Borovoy M.A., Borovoy M., Elxon L.M., et al. Flashlamp pulsed dye laser (585 mn) treatment of resistant verrucae. J Am Pod Med Assoc 1996; 86 (11): 547–550Google Scholar
Alec M., Ursaciuc C., Halalau F., et al. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hyercin. Anticancer Res 1998; 18 (6B): 4561–4564Google Scholar
Hurliman A.F., Hanggi G., Panzzon R.G. Photodynamic therapy of superficial basal cell carcinomas using topical 5 aminolevulinic acid in a noncolloid lotion. Dermatology1998; 197 (3): 248–254CrossRefGoogle Scholar
Kurwa H.A., Yong Gee S.A., Seed P.T., et al. A randomised paired comparison of photodynamic therapy and topical 5 fluorouracil in the treatment of actinic keratoses.J Am Acad Dermatol 1999; 41 (3 Pt 1): 414–418PubMedCrossRefGoogle Scholar
Szimies R.M., Karrer S., Sauerwald A., et al. Photodynamic therapy with topical 5 aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study.Dermatology 1996; 192 (3): 246–51CrossRefGoogle Scholar
Stender I.N.I., Wulf H.C. The treatment of recalcitrant verrucae by Photodynamic therapy with topical delta aminolaevulinic acid [letter]. Clin Exp Dermatol; 1996: 21: 388–396CrossRefGoogle Scholar
Stender I.M., Na R., Fogh H., et al. Photodynamic therapy with 5 aminolaevulinic acid or placebo for recalcitrant foot and hand warts; a randomised double blind trial. Lancet 2000; 555: 963–966CrossRefGoogle Scholar